Johnson & Johnson built much of its pharmaceutical muscle through shrewd biotech partnerships rather than blockbuster acquisitions, locking in future profits at bargain prices. That strategy produced stellar returns but carries a structural flaw: its partners remain independent, free to negotiate with deeper-pocketed rivals at any moment. For years, this capital-light dealmaking defined the healthcare giant's expansion, though surging biotech valuations and intense competitive pressure are now exposing the model's hard limitations.

The blood-cancer therapy Imbruvica illustrates the downside in stark terms. J&J secured half the profits from Pharmacyclics for less than $1 billion, a steal for what became a blockbuster drug. Once the treatment won regulatory approval, AbbVie paid $21 billion to acquire Pharmacyclics outright in 2015, forcing J&J into an awkward profit-sharing marriage with a fierce competitor. The episode left J&J collecting hefty royalties but strategically sidelined from controlling the asset's full commercial destiny.

More recently, J&J tried to avoid a repeat by holding acquisition talks with Protagonist Therapeutics, its autoimmune-disease partner. No deal closed, and the biotech's stock has since surged, making an affordable buyout unlikely. The situation delivers a blunt message to J&J: in a market where rivals pay premiums for proven biotech assets, partnerships that once delivered outsized upside now leave the company exposed, cash-rich yet vulnerable to getting outbid on the drugs it helped validate.